Publication | Closed Access
Prognostic factors for favorable outcome in disseminated germ cell tumors.
295
Citations
4
References
1986
Year
Prognostic FactorsSurgical OncologyIndiana UniversityCancer ManagementEpidemiology Of CancerPathologyCancer RegistrationExtragonadal Germ Cell TumoursPrognostic SignificanceIndiana Staging SystemNeuro-oncologyOncologyGenitourinary CancerSurgical PathologyMetronomic TherapyRadiation OncologyCancer ResearchRadiologyHealth SciencesCancer PrognosisCancer TreatmentMalignant DiseaseGerm Cell NeoplasiaTumoral PathologyMedicine
The study employed a randomized SECSG protocol comparing PVB with PVB plus doxorubicin induction, then used logistic regression to assess prognostic factors, focusing on the Indiana and MDA staging systems. Favorable responses were achieved in 82 % of patients, with the Indiana staging system proving highly prognostic by separating patients into minimal (99 % favorable), moderate (90 %), and advanced (58 %) groups, and further stratifying advanced disease by tumor marker levels into 73 %, 65 %, and 45 % favorable response rates.
Between 1978 and 1982, 180 patients from Indiana University (Indianapolis) were entered on the Southeastern Cancer Study Group (SECSG) protocol 78 GU 240, a randomized comparison of cisplatin, vinblastine, and bleomycin (PVB) v PVB plus doxorubicin induction chemotherapy regimens, with a second randomization to maintenance vinblastine v no further therapy. One hundred forty-eight of these patients obtained a favorable response to chemotherapy, defined as a complete response (CR) or a surgical resection of teratoma. The prognostic significance of various patient characteristics was investigated using the logistic regression model. Two classifications for the extent of disease were considered: the Indiana staging system and the M.D. Anderson (MDA) staging system. The Indiana staging system had the greater prognostic significance. This staging system allowed the population to be split into three groups (minimal, moderate, advanced disease) in which the observed proportions of favorable responders were 99%, 90%, and 58%, respectively. Within the advanced group, the number of elevated tumor markers subdivided these patients into three groups, with the observed proportions of favorable responders being 73%, 65%, and 45%. The Indiana and MDA staging systems were subsequently prospectively used in SECSG protocol GU 81 332, a study randomizing patients to remission induction therapy with PVB v cisplatin, VP-16, and bleomycin. The prognostic value of the Indiana staging system was prospectively validated in this study.
| Year | Citations | |
|---|---|---|
Page 1
Page 1